GSK plc Sponsored ADR (GSK)
GSK's asthma drug shows promise in reducing severe attacks
GSK's asthma drug met its primary goal of reducing asthma attacks over a 52-week period in a late-stage trial, the British drugmaker said on Tuesday.
GSK faces whistleblower lawsuit over Zantac cancer risk
GSK has been sued by an independent Connecticut laboratory that accused the drugmaker of defrauding the U.S. government and taxpayers by concealing cancer risks in Zantac, once a blockbuster heartburn drug.
GSK confirms exit of Haleon stake for £3.9 billion
GSK PLC (LSE:GSK, NYSE:GSK) confirmed it has raised a total of £3.9 billion through the exit of its stake in Haleon PLC (LSE:HLN, NYSE:HLN), the healthcare firm which was spun out by the pharma giant back in 2022. On Friday, the Brentford-based firm revealed it raised £1.24 billion after it sold the final part of its stake in Haleon, offloading more than 385 million shares at 324p each.
GSK raises $1.5 bln from offloading Haleon stake at a discount
GSK has raised 1.25 billion pounds ($1.52 billion) from selling its entire remaining stake in consumer healthcare firm Haleon, the British drugmaker said on Friday.
GSK intends to sell its remaining stake in Haleon
British drugmaker GSK said on Thursday it plans to sell about 385 million shares, representing its entire shareholding, in spun-off consumer healthcare business Haleon.
